Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment

Fineline Cube Apr 16, 2026
Company Deals

Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development

Fineline Cube Apr 16, 2026
Company Deals

GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235

Fineline Cube Apr 16, 2026
Company Deals

Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision

Fineline Cube Apr 16, 2026
Company Deals Drug

Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers

Fineline Cube Apr 16, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Fineline Cube Apr 16, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Fineline Cube Apr 16, 2026
Policy / Regulatory

Frontier Biotech’s FB2001 Inhalant Accepted for NMPA Review

Fineline Cube Sep 14, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced that a registrational clinical filing for its FB2001...

Company Drug

Luye Pharma’s LY03015 Receives FDA Approval for Phase I Clinical Study

Fineline Cube Sep 14, 2022

China-based Luye Pharma Group (HKG: 2186) announced that it has received approval from the US...

Company Deals

Hengrui Medicine to Incentivize Employees with Share Distribution

Fineline Cube Sep 14, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced plans to incentivize its employees...

Policy / Regulatory

Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise

Fineline Cube Sep 13, 2022

US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...

Company Deals

QuantuMDx and Sansure Biotech Partner to Commercialize Q-POC in China

Fineline Cube Sep 13, 2022

UK-based QuantuMDx Group Ltd announced a global R&D, manufacturing, and commercial partnership with China’s Sansure...

Company Drug

InnoCare Pharma’s BCL2 Inhibitor ICP-248 Gains NMPA Approval for Clinical Study

Fineline Cube Sep 13, 2022

China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National...

Company Drug

BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO

Fineline Cube Sep 13, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) presented the latest results of the global Phase...

Company Drug

Luye Pharma’s BA-CovMab Receives NMPA Approval for COVID-19 Clinical Trials

Fineline Cube Sep 13, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...

Policy / Regulatory

Jiangsu Healthcare to Cover All Psychological Treatments Under BMI

Fineline Cube Sep 13, 2022

The Jiangsu Provincial Healthcare Security Administration is reportedly considering adding all psychological diagnosis and treatment...

Company Deals

Leadinno Medical Valley Raises RMB 100M in Series A Financing for Neuromodulation Devices

Fineline Cube Sep 13, 2022

Beijing-based neuromodulation medical device maker Leadinno Medical Valley reportedly raised over RMB 100 million (USD...

Company Drug

Transcenta’s TST001 Shows Promise in Gastric Cancer Trial with 73.3% Response Rate

Fineline Cube Sep 13, 2022

China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced interim safety and efficacy data from a...

Company Drug

CSPC Pharmaceutical’s TG103 Gains NMPA Approval for NASH and Alzheimer’s Trials

Fineline Cube Sep 13, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company Drug

Jingxin Pharmaceutical Receives NMPA Approval for JBPOS0101 and JX7002 Trials

Fineline Cube Sep 13, 2022

Jingxin Pharmaceutical Co., Ltd (SHE: 002020) announced that it has received clinical trial approvals from...

Drug

China’s Retail Pharmacy O2O Sales Surge to USD 2.9B in 2021

Fineline Cube Sep 9, 2022

According to the “China Retail Pharmacy O2O Development Report” released by Minenet, the “online drug...

Medical Device Policy / Regulatory

National High-Value Medical Consumables VBP Round Targets Orthopedic Spine Products

Fineline Cube Sep 9, 2022

The national high-value medical consumables joint procurement office released a set of guiding opinions on...

Company Drug

China’s Cecolin HPV Vaccine Shows 100% Efficacy in 66-Month Study

Fineline Cube Sep 9, 2022

Chinese researchers have published 66-month follow-up data from a Phase III clinical study for the...

Company Drug

Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial

Fineline Cube Sep 9, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval...

Company Policy / Regulatory

MofCOM’s 2021 Pharma Distribution Report Shows Market Recovery

Fineline Cube Sep 9, 2022

The Ministry of Commerce (MofCOM) released its annual statistical review of the pharma distribution industry...

Policy / Regulatory

NHSA Issues Notice on Special Treatment of Oral Implant Medical Service Charges

Fineline Cube Sep 9, 2022

The National Healthcare Security Administration (NHSA) has released a Notice on “Carrying out Special Treatment...

Company Drug

Keymed and Lepu’s CMG901 Receives Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Sep 9, 2022

The Center for Drug Evaluation (CDE) website indicates that CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody...

Posts pagination

1 … 612 613 614 … 652

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty
  • Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration
  • Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer
  • Mabwell Bioscience Secures Second NMPA Approval for Denosu, China’s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma
  • CSPC Pharmaceutical Secures NMPA Clinical Trial Approval for SYS6051, a Tissue Factor-Targeted ADC for Advanced Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Company Drug

Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer

Company Drug

Mabwell Bioscience Secures Second NMPA Approval for Denosu, China’s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.